StreetInsider.com News Articles

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Thu, 03 Sep 2026 07:15:00 -0400

LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m. ET.

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Thu, 03 Sep 2026 07:15:00 -0400

ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim

Mon, 17 Aug 2026 07:12:59 -0400

(Updated - August 17, 2026 7:12 AM EDT)

Guggenheim analyst Michael Schmidt lowered the price target on ADC Therapeutics (NYSE: ADCT) to $5.00 (from $10.00) while maintaining a Buy rating.

The analyst commented: "ADCT reported 2Q results and provided updates on development of Zynlonta in 2L+ DLBCL. Recall, in June, ADCT announced topline results from the confirmatory Phase 3 LOTIS-5 study (Zynlonta + rituximab) which met its primary efficacy endpoint of PFS (HR 0.73), but did not improve OS (HR=0.96) and had an elevated frequency of Grade 5 TEAEs in the Zynlonta + R arm of the study (see our note). Management

ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim

Mon, 17 Aug 2026 07:12:59 -0400

(Updated - August 17, 2026 7:12 AM EDT)

Guggenheim analyst Michael Schmidt lowered the price target on ADC Therapeutics (NYSE: ADCT) to $5.00 (from $10.00) while maintaining a Buy rating.

Form SCHEDULE 13G ADC Therapeutics SA Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931902.html

Form SCHEDULE 13G ADC Therapeutics SA Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931902.html

Form S-8 ADC Therapeutics SA

Thu, 13 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260813/26922282.html

Form S-8 ADC Therapeutics SA

Thu, 13 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260813/26922282.html

Form 10-Q ADC Therapeutics SA For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921090.html

Form 10-Q ADC Therapeutics SA For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921090.html

Form 8-K ADC Therapeutics SA For: Aug 13

Thu, 13 Aug 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26917626.html

Form 8-K ADC Therapeutics SA For: Aug 13

Thu, 13 Aug 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26917626.html

ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c

Thu, 13 Aug 2026 07:32:27 -0400

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.11), $0.11 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $19.25 million versus the consensus estimate of $18.89 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Thu, 13 Aug 2026 07:30:00 -0400

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH

Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational